Document is current
Any future updates will be listed below
-
Authors
van de Berg, S. E. J.
Pelzer, P. T. http://orcid.org/0000-0003-1648-0304
van der Land, A. J.
Abdrakhmanova, E.
Ozi, A. Muhammad
Arias, M.
Cook-Scalise, S.
Dravniece, G.
Gebhard, A.
Juneja, S.
Handayani, R.
Kappel, D.
Kimerling, M.
Koppelaar, I.
Malhotra, S.
Myrzaliev, B.
Nsa, B.
Sugiharto, J.
Engel, N.
Mulder, C.
van den Hof, S.
-
Funding
Funding for this research was provided by:
Global Alliance for TB Drug Development
- License Information
-
More Information
Article History
Received: 26 October 2020
Accepted: 30 June 2021
First Online: 16 July 2021
Declarations
:
: All study participants provided written informed consent for participation in the study and for audio recording. All data were kept confidential and anonymous. To enhance confidentiality, results for specific stakeholder groups were aggregated for each specific country. Ethical approval was obtained from the Ethical committee of Scientific and Production Centre of Preventive Medicine of the Ministry of Health of the Kyrgyz Republic and the Ethical committee of Atmajaya University, Jakarta. A waiver was received from the National Health Research Ethics Committee in Nigeria.
: Not applicable.
: All authors declare that they have no competing interests except SM, SCS, DK, and SJ are current or former employees of TB Alliance, the sponsor of the Nix-TB trial and license-holder of pretomanid.
